These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

76 related items for PubMed ID: 7521423

  • 1. [Study for relapse cases of chronic hepatitis C treated with interferon (IFN) and approach to more successful re-treatment of IFN].
    Iwabuchi S, Yoshida H, Fukui S.
    Nihon Rinsho; 1994 Jul; 52(7):1810-6. PubMed ID: 7521423
    [Abstract] [Full Text] [Related]

  • 2. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
    Mamori S, Suzuki F, Hosaka T, Akuta N, Someya T, Kobayashi M, Tsubota A, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H.
    J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
    [Abstract] [Full Text] [Related]

  • 3. [Clinical study of retreatment of chronic hepatitis C with interferon (IFN) for non-complete responders on initial treatment].
    Toyoda H, Nakano S, Kumada T.
    Nihon Rinsho; 1994 Jul; 52(7):1798-803. PubMed ID: 7521421
    [Abstract] [Full Text] [Related]

  • 4. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y, Bayraktar M, Gurakar A, Hassanein TI, Van Thiel DH.
    Hepatogastroenterology; 1997 Jul; 44(14):417-25. PubMed ID: 9164512
    [Abstract] [Full Text] [Related]

  • 5. Retreatment of chronic hepatitis C with interferon.
    Toyoda H, Nakano S, Takeda I, Kumada T, Sugiyama K, Osada T, Kiriyama S, Suga T, Ohki H, Ito O.
    Am J Gastroenterol; 1994 Sep; 89(9):1453-7. PubMed ID: 7521572
    [Abstract] [Full Text] [Related]

  • 6. [Significance of total dose of IFN in the treatment of chronic hepatitis C].
    Imazeki F, Yokosuka O.
    Nihon Rinsho; 1994 Jul; 52(7):1794-7. PubMed ID: 7521420
    [Abstract] [Full Text] [Related]

  • 7. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR.
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [Abstract] [Full Text] [Related]

  • 8. [Examination in clinical course of HCV in interferon treatment].
    Kumada H.
    Nihon Rinsho; 1994 Jul; 52(7):1832-5. PubMed ID: 7521426
    [Abstract] [Full Text] [Related]

  • 9. [The indication and the evaluation of IFN treatment of chronic hepatitis C].
    Yano M.
    Nihon Rinsho; 1994 Jul; 52(7):1778-83. PubMed ID: 7521417
    [Abstract] [Full Text] [Related]

  • 10. [Serum HCV-RNA for evaluation of interferon-readministration to the former non responders in chronic hepatitis C].
    Sata M, Tanikawa K.
    Nihon Rinsho; 1994 Jul; 52(7):1804-9. PubMed ID: 7521422
    [Abstract] [Full Text] [Related]

  • 11. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.
    Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V.
    Hepatology; 1995 Oct; 22(4 Pt 1):1050-6. PubMed ID: 7557850
    [Abstract] [Full Text] [Related]

  • 12. Choice of appropriate end points of response to interferon therapy in chronic hepatitis C virus infection.
    Davis GL, Lau JY.
    J Hepatol; 1995 Oct; 22(1 Suppl):110-4. PubMed ID: 7602061
    [Abstract] [Full Text] [Related]

  • 13. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial.
    Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, Masuzawa M, Yoshihara H, Kishida Y.
    Hepatology; 1995 Feb; 21(2):291-7. PubMed ID: 7843696
    [Abstract] [Full Text] [Related]

  • 14. Treatment of chronic hepatitis C with interferon alpha: long-term follow-up and prognostic relevance of HCV genotypes.
    Hopf U, Berg T, König V, Küther S, Heuft HG, Lobeck H.
    J Hepatol; 1996 Feb; 24(2 Suppl):67-73. PubMed ID: 8836892
    [Abstract] [Full Text] [Related]

  • 15. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C.
    Karino Y, Toyota J, Sugawara M, Higashino K, Sato T, Ohmura T, Suga T, Okuuchi Y, Matsushima T.
    Am J Gastroenterol; 1997 Jan; 92(1):61-5. PubMed ID: 8995939
    [Abstract] [Full Text] [Related]

  • 16. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta.
    Kobayashi Y, Watanabe S, Konishi M, Yokoi M, Kakehashi R, Kaito M, Kondo M, Hayashi Y, Jomori T, Suzuki S.
    Hepatology; 1993 Dec; 18(6):1319-25. PubMed ID: 8244255
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Serum levels of HCV-RNA determined by branched DNA (bDNA) probe assay in chronic hepatitis C: method and clinical significance on interferon (IFN) therapy].
    Osada T, Iwabuchi S, Takatori M, Murayama M, Iino S.
    Nihon Rinsho; 1994 Jul; 52(7):1747-53. PubMed ID: 7521414
    [Abstract] [Full Text] [Related]

  • 19. [A trial of new interferon therapy for the patients with chronic hepatitis C resistant to interferon therapy].
    Arase Y, Kumada H.
    Nihon Rinsho; 2001 Jul; 59(7):1309-14. PubMed ID: 11494543
    [Abstract] [Full Text] [Related]

  • 20. [Prediction of the outcome of IFN therapy in type C chronic hepatitis from serological grouping of hepatitis C virus].
    Sakai A, Yanagi M, Unoura M, Kobayashi K.
    Nihon Rinsho; 1994 Jul; 52(7):1759-62. PubMed ID: 7521415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.